CYBORGEL: UC Davis $36.5M ARPA-H cell therapy storage timeline

University of California, Davis USA

Overview

The UC Davis-led CYBORGEL project has been awarded up to $36.5 million in ARPA-H funding to pioneer room-temperature storage solutions for cellular therapies. This initiative aims to drastically reduce current cold-chain logistics costs and enhance accessibility by using intracellular gelation to create ‘cyborg’ cell-material hybrids that preserve cellular function during ambient storage and shipping. The project plans to validate the therapeutic efficacy of reanimated CAR T cells stored with this novel process in clinical settings, potentially transforming the global distribution of advanced cell therapies.

In Depth

Key Findings

The University of California, Davis-led CYBORGEL project has secured up to $36.5 million in funding from the Advanced Research Projects Agency for Health (ARPA-H) to develop a groundbreaking room-temperature storage technology for cellular therapies. This innovative approach promises to significantly lower the logistical costs and expand the global accessibility of life-saving cell-based treatments.

Technical / Clinical Details

At the core of the CYBORGEL project is the “intracellular gelation” technique, which involves introducing a biocompatible gelling agent directly into cells. This process transforms cells into “cyborg” cell-material hybrids capable of maintaining structural integrity and functional viability even in a desiccated state at ambient temperatures. Upon rehydration, these cells are designed to regain their full therapeutic potential. This technology directly addresses the current reliance on expensive and complex ultra-cold chain logistics (e.g., liquid nitrogen storage) for sensitive cellular products like CAR-T cells. The next phase of the project will involve rigorous testing of the stored and reanimated CAR-T cells to confirm their efficacy and safety in preclinical models, with ultimate validation in clinical environments.

Background & Context

Current cell therapies, including CAR-T cell treatments, necessitate ultra-cold storage and transportation, which are major drivers of exorbitant manufacturing and distribution costs. These logistical constraints restrict the delivery of these advanced treatments to specialized facilities with cryogenic capabilities, severely limiting access in remote areas and developing countries. The CYBORGEL project’s room-temperature storage solution could democratize access to cell therapies globally, bypassing the need for extensive cold-chain infrastructure. This represents a significant leap towards equity in healthcare and a potential commercial breakthrough for the cell therapy industry.

Strategic Significance & Outlook

Successful implementation of room-temperature storage could streamline the entire cell therapy supply chain, from manufacturing to patient administration, leading to multi-million dollar cost reductions. This could, in turn, contribute to lowering the currently high treatment costs, making these transformative therapies available to a much broader patient population. Beyond CAR-T cells, this technology holds promise for various other cell-based therapeutics and regenerative medicine products, such as iPS cells, NK cells, and tissue-engineered constructs, potentially impacting the entire biopharmaceutical sector on a global scale.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime